Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320642 · ClinicalTrials.gov registry record · Phase 1
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT03320642 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 84 participants.
The verdict
NCT03320642, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
Interventions
- DRUG Itacitinib
- DRUG Calcineurin inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03320642
The ClinicalTrials.gov registry entry for NCT03320642 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itacitinib is the first listed.
NCT03320642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03320642 about?
NCT03320642 is a clinical study titled "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease". The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
What is the current status of trial NCT03320642?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2018-02-27. Estimated completion is 2022-02-17.
What interventions are being tested in trial NCT03320642?
The interventions under investigation include: Itacitinib (DRUG), Calcineurin inhibitor (DRUG).
Who is sponsoring clinical trial NCT03320642?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.